Live Quote · NASDAQCADLHealthcare· Biotechnology

Candel Therapeutics, Inc.

$9.83 0.51%($-0.05)
TickerSpark Score
67/100
Solid
73
Valuation
20
Profitability
60
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CADL research report →

52-Week Range78% of range
Low
$4.35
Current
$9.83
High
$11.36
Company Overviewwww.candeltx.com

About the company

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer.

CEO
Paul-Peter Tak
IPO
2021
Employees
38
HQ
Needham, MA, US

Price Chart

+96.99% · this period
$10.36$7.39$4.42Jul 02Dec 31Jul 02
Valuation
Market Cap
$539.68M
P/E
-10.00
P/S
0.00
P/B
4.44
EV/EBITDA
-6.89
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-60.42%
ROIC
-28.89%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-38,182,000 · 30.80%
EPS
$-0.72 · 58.62%
Op Income
$-48,266,000
FCF YoY
-43.86%
Performance & Tape
52W High
$11.36
52W Low
$4.35
50D MA
$8.25
200D MA
$6.11
Beta
-0.51
Avg Volume
2.09M

Get TickerSpark's AI analysis on CADL

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 29, 26Barone Francescasell23,447
Jun 29, 26Tyagarajan Seshusell7,000
Jun 30, 26Manning Paul Bother2,199
Jun 30, 26PAPA JOSEPH Cother1,331
Jun 30, 26Loggia Nicolettaother381
Jun 23, 26Radhakrishnan Mahaother32,000
Jun 23, 26Loggia Nicolettaother32,000
Jun 23, 26PAPA JOSEPH Cother32,000
Jun 23, 26Benz Edward J. JRother32,000
Jun 23, 26Martell Christopherother32,000
Coverage · CADL

Our CADL coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CADL yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CADL report →
Internal Compare

Similar companies

Peers in the same neighborhood.